.jpg?format=webp&width=780)
HSP90 is a downstream regulator of tumour necrosis factor (TNF)‐α and interleukin (IL)‐17A signalling and may serve as a novel target in the treatment of psoriasis. This phase Ib proof‐of‐concept study was undertaken to evaluate the safety and efficacy of a novel HSP90 inhibitor (RGRN‐305) in treating plaque psoriasis. Treatment with RGRN‐305 showed acceptable safety, especially in the low‐dose group, and was associated with clinically meaningful improvement in a subset of patients with plaque psoriasis, indicating that HSP90 may serve as a novel future target in psoriasis treatment.
Like
Save
Share